يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Robinson-Bennett B."', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المؤلفون: Vergote I., Scambia G., O'Malley D. M., Van Calster B., Park S. -Y., del Campo J. M., Meier W., Bamias A., Colombo N., Wenham R. M., Covens A., Marth C., Raza Mirza M., Kroep J. R., Ma H., Pickett C. A., Monk B. J., Park S. Y., Song Y. S., Makarova Y., Trinidad J., Ngan H. Y. S., Aravantinos G., Nam J. -H., Gorbunova V., Krikunova L., Bae D. -S., Arija J. A. A., Mirza M. R., Zamagni C., Papandreou C., Raspagliesi F., Lisyanskaya A., Benzaquen A. O., Tognon G., Ortega E., Herraez A. C., Buscema J., Green A., Burger R., Sakaeva D., Sanchez A. R., Ghamande S., King L., Petru E., Peen U., Takeuchi S., Ushijima K., Martin A. G., Kamelle S., Carney M., Forget F., Bentley J., Sehouli J., Zola P., Kato H., Fadeeva N., Gotovkin E., Vladimirov V., Marin M. R., Alia E. G., Shahin M., Bhoola S., Tewari K., Anderson D., Honhon B., Pelgrims J. G., Oza A., Jimenez J. G. -D., Hansen V., O'Malley D., Benjamin I., Renard V., Van den Bulck H., Haenle C., Koumakis G., Yokota H., Popov V., Bradley W., Wenham R., Reid R., McNamara D., Friedman R., Barlin J., Spirtos N., Chapman J., Sevelda P., Huizing M., Lamot C., Goffin F., Hondt L. D., Spadafora S., Rautenberg B., Reimer T., Mobus V., Hilpert F., Gropp-Meier M., Savarese A., Pignata S., Verderame F., Mizuno M., Takano H., Ottevanger P., Velasco A. P., Palacio-Vazquez I., Law A., McIntyre K., Teneriello M., Fields A., Lentz S., Street D., Schwartz B., Mannel R., Lim P., Pulaski H., Janni W., Zorr A., Karck U., Cheng A. C. K., Sorio R., Gridelli C., Aoki D., Oishi T., Hirashima Y., Boere I., Ferrer E. F., Braly P., Wilks S., Lee C., Schilder J., Veljovich D., Secord A., Davis K., Rojas-Espaillat L., Lele S., DePasquale S., Squatrito R., Schauer C., Dirix L., Vuylsteke P., Joosens E., Provencher D., Lueck H. -J., Hein A., Burges A., Canzler U., Park-Simon T. -W., Griesinger F., Gadducci A., Alabiso O., Okamoto A., Sawasaki T., Saito T., Ibanez A. H., Calomeni C., Spillman M., Choksi J., Taylor N., Muller C., Moore D., DiSilvestro P., Cunningham M., Rose P., Oppelt P., Verhoeven D., Graas M. -P., Ghatage P., Tonkin K., Kurzeder C., Schnappauf B., Muller V., Schmalzrie H., Kalofonos H., Bruzzone M., Kroep J., Diaz C. C., Garcia J. M., Polo S. H., Garrison M., Rocconi R., Andrews S., Bristow R., McHale M., Basil J., Houck III W., Bell M., Cosin J., Modesitt S., Kendrick J., Wade III J., Wong C., Evans A., Buekers T., Vanderkwaak T., Ferriss J., Darus C., DAndre S., Higgins R., Monk B., Bakkum-Gamez J., DeMars L., Van Le L., Puls L., Trehan S., LaPolla J., Michelson E. D., Merchant J., Peterson C., Reid G., Seago D., Zweizig S., Gajewski W., Panwalkar A., Leikermoser R., Bogner G., Debruyne P., D'hondt R., Berteloot P., Kerger J., Biagi J., Castonguay V., Welch S., Muhic A., Heubner M., Grischke E. -M., Rack B., Fleisch M., Lordick F., Pectasides D., Ho W. M., Selvaggi L., Vasquez F. M., Villanueva W. O. B., Alavez A. M., Kessels L., Bertran A. S., Fernandez C. M., Fabregat M. B., Del Prete S., Elkas J., Cecchi G., Kumar P., Huh W., Messing M., Karimi M., Kelley A., Edraki B., Mutch D., Leiserowitz G., Anderson J., Chambers S., Morris R., Waggoner S., Gordon A., Method M., Johnson P., Lord R., Drake J., Sivarajan K., Midathada M., Rice K., Wadsworth T., Pavelka J., Edwards R., Miller D. S., Ford P. L., Hurteau J., Bender D., Schimp V., Creasman W., Lerner R., Chamberlain D., Kueck A., McDonald J., Malad S., Robinson-Bennett B., Davidson S., Krivak T., Lestingi T., Arango H., Berard P., Finkelstein K., Gaur R., Krasner C., Ueland F., Talmage L., Yamada S., Sutton G., Potkul R., Prasad-Hayes M., Osborne J., Celano P., Thigpen J., Sharma S., Schilder R., Tammela J., Kemeny M., Brown A., Eisenhauer E., Williams J., Rowland K., Nahum K., Burke J., Dar Z., Fleming N., Gibb R., Guirguis A., Herzog T., John V., Kumar S., Kamat A., Kassar M., Leitao M., Levine L., Mendez L., Patel D., Berry E., Warshal D., Wolf J., Zarwan C., Collins Y., Spitzer G., Miller B., Einstein M.

    المساهمون: Vergote I., Scambia G., O'Malley D.M., Van Calster B., Park S.-Y., del Campo J.M., Meier W., Bamias A., Colombo N., Wenham R.M., Covens A., Marth C., Raza Mirza M., Kroep J.R., Ma H., Pickett C.A., Monk B.J., Park S.Y., Song Y.S., Makarova Y., Trinidad J., Ngan H.Y.S., Aravantinos G., Nam J.-H., Gorbunova V., Krikunova L., Bae D.-S., Arija J.A.A., Mirza M.R., Zamagni C., Papandreou C., Raspagliesi F., Lisyanskaya A., Benzaquen A.O., Tognon G., Ortega E., Herraez A.C., Buscema J., Green A., Burger R., Sakaeva D., Sanchez A.R., Ghamande S., King L., Petru E., Peen U., Takeuchi S., Ushijima K., Martin A.G., Kamelle S., Carney M., Forget F., Bentley J., Sehouli J., Zola P., Kato H., Fadeeva N., Gotovkin E., Vladimirov V., Marin M.R., Alia E.G., Shahin M., Bhoola S., Tewari K., Anderson D., Honhon B., Pelgrims J.G., Oza A., Jimenez J.G.-D., Hansen V., O'Malley D., Benjamin I., Renard V., Van den Bulck H., Haenle C., Koumakis G., Yokota H., Popov V., Bradley W., Wenham R., Reid R., McNamara D., Friedman R., Barlin J., Spirtos N., Chapman J., Sevelda P., Huizing M., Lamot C., Goffin F., Hondt L.D., Spadafora S., Rautenberg B., Reimer T., Mobus V., Hilpert F., Gropp-Meier M., Savarese A., Pignata S.

    الوصف: Background: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. Methods: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres)in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO)stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1)using a permuted block method (block size of six patients)to receive six cycles of paclitaxel (175 mg/m2)and carboplatin (area under the serum concentration-time curve 5 or 6)every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete. Findings: Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7–34·2), 626 patients had progression-free survival events (405 [60%]of 678 in the trebananib group and 221 [66%]of 337 in the placebo group). Median progression-free survival did not differ ...

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31076365; info:eu-repo/semantics/altIdentifier/wos/WOS:000469336000054; volume:20; issue:6; firstpage:862; lastpage:876; numberofpages:15; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/2318/1730319Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85066276936; http://www.journals.elsevier.com/the-lancet-oncologyTest/

  2. 2

    المؤلفون: Vergote, I. Scambia, G. O'Malley, D.M. Van Calster, B. Park, S.-Y. del Campo, J.M. Meier, W. Bamias, A. Colombo, N. Wenham, R.M. Covens, A. Marth, C. Raza Mirza, M. Kroep, J.R. Ma, H. Pickett, C.A. Monk, B.J. Park, S.Y. Song, Y.S. Makarova, Y. Trinidad, J. Ngan, H.Y.S. Aravantinos, G. Nam, J.-H. Gorbunova, V. Krikunova, L. Bae, D.-S. Arija, J.A.A. Mirza, M.R. Zamagni, C. Papandreou, C. Raspagliesi, F. Lisyanskaya, A. Benzaquen, A.O. Tognon, G. Ortega, E. Herraez, A.C. Buscema, J. Green, A. Burger, R. Sakaeva, D. Sanchez, A.R. Ghamande, S. King, L. Petru, E. Peen, U. Takeuchi, S. Ushijima, K. Martin, A.G. Kamelle, S. Carney, M. Forget, F. Bentley, J. Sehouli, J. Zola, P. Kato, H. Fadeeva, N. Gotovkin, E. Vladimirov, V. Marin, M.R. Alia, E.G. Shahin, M. Bhoola, S. Tewari, K. Anderson, D. Honhon, B. Pelgrims, J.G. Oza, A. Jimenez, J.G.-D. Hansen, V. Benjamin, I. Renard, V. Van den Bulck, H. Haenle, C. Koumakis, G. Yokota, H. Popov, V. Bradley, W. Wenham, R. Reid, R. McNamara, D. Friedman, R. Barlin, J. Spirtos, N. Chapman, J. Sevelda, P. Huizing, M. Lamot, C. Goffin, F. Hondt, L.D. Covens, A. Spadafora, S. Rautenberg, B. Reimer, T. Möbus, V. Hilpert, F. Gropp-Meier, M. Savarese, A. Pignata, S. Verderame, F. Mizuno, M. Takano, H. Ottevanger, P. Velasco, A.P. Palacio-Vazquez, I. Law, A. McIntyre, K. Teneriello, M. Fields, A. Lentz, S. Street, D. Schwartz, B. Mannel, R. Lim, P. Pulaski, H. Janni, W. Zorr, A. Karck, U. Cheng, A.C.K. Sorio, R. Gridelli, C. Aoki, D. Oishi, T. Hirashima, Y. Boere, I. Ferrer, E.F. Braly, P. Wilks, S. Lee, C. Schilder, J. Veljovich, D. Secord, A. Davis, K. Rojas-Espaillat, L. Lele, S. DePasquale, S. Squatrito, R. Schauer, C. Dirix, L. Vuylsteke, P. Joosens, E. Provencher, D. Lueck, H.-J. Hein, A. Burges, A. Canzler, U. Park-Simon, T.-W. Griesinger, F. Gadducci, A. Alabiso, O. Okamoto, A. Sawasaki, T. Saito, T. Ibañez, A.H. Calomeni, C. Spillman, M. Choksi, J. Taylor, N. Muller, C. Moore, D. DiSilvestro, P. Cunningham, M. Rose, P. Oppelt, P. Verhoeven, D. Graas, M.-P. Ghatage, P. Tonkin, K. Kurzeder, C. Schnappauf, B. Müller, V. Schmalzrie, H. Kalofonos, H. Bruzzone, M. Kroep, J. Diaz, C.C. Garcia, J.M. Polo, S.H. Garrison, M. Rocconi, R. Andrews, S. Bristow, R. McHale, M. Basil, J. Houck III, W. Bell, M. Cosin, J. Modesitt, S. Kendrick, J. Wade III, J. Wong, C. Evans, A. Buekers, T. Vanderkwaak, T. Ferriss, J. Darus, C. DAndre, S. Higgins, R. Monk, B. Bakkum-Gamez, J. DeMars, L. Van Le, L. Puls, L. Trehan, S. LaPolla, J. Michelson, E.D. Merchant, J. Peterson, C. Reid, G. Seago, D. Zweizig, S. Gajewski, W. Panwalkar, A. Leikermoser, R. Bogner, G. Debruyne, P. D'hondt, R. Berteloot, P. Kerger, J. Biagi, J. Castonguay, V. Welch, S. Muhic, A. Heubner, M. Grischke, E.-M. Rack, B. Fleisch, M. Lordick, F. Pectasides, D. Ho, W.M. Selvaggi, L. Vasquez, F.M. Villanueva, W.O.B. Alavez, A.M. Kessels, L. Bertran, A.S. Fernandez, C.M. Fabregat, M.B. Del Prete, S. Elkas, J. Cecchi, G. Kumar, P. Huh, W. Messing, M. Karimi, M. Kelley, A. Edraki, B. Mutch, D. Leiserowitz, G. Anderson, J. Lentz, S. Chambers, S. Morris, R. Waggoner, S. Gordon, A. Method, M. Johnson, P. Lord, R. Drake, J. Sivarajan, K. Midathada, M. Rice, K. Wadsworth, T. Pavelka, J. Edwards, R. Miller, D.S. Ford, P.L. Hurteau, J. Bender, D. Schimp, V. Creasman, W. Lerner, R. Chamberlain, D. Kueck, A. McDonald, J. Malad, S. Robinson-Bennett, B. Davidson, S. Krivak, T. Lestingi, T. Arango, H. Berard, P. Finkelstein, K. Gaur, R. Krasner, C. Ueland, F. Talmage, L. Yamada, S. Sutton, G. Potkul, R. Prasad-Hayes, M. Osborne, J. Celano, P. Thigpen, J. Sharma, S. Schilder, R. Tammela, J. Kemeny, M. Brown, A. Eisenhauer, E. Williams, J. Rowland, K. Nahum, K. Burke, J. Dar, Z. Fleming, N. Gibb, R. Guirguis, A. Herzog, T. John, V. Kumar, S. Kamat, A. Kassar, M. Leitao, M. Levine, L. Mendez, L. Patel, D. Berry, E. Warshal, D. Wolf, J. Zarwan, C. Collins, Y. Spitzer, G. Miller, B. Einstein, M. TRINOVA-3/ENGOT-ov2/GOG-3001 investigators

    الوصف: Background: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. Methods: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres)in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO)stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1)using a permuted block method (block size of six patients)to receive six cycles of paclitaxel (175 mg/m2)and carboplatin (area under the serum concentration-time curve 5 or 6)every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete. Findings: Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7–34·2), 626 patients had progression-free survival events (405 [60%]of 678 in the trebananib group and 221 [66%]of 337 in the placebo group). Median progression-free survival did not differ between the trebananib group (15·9 months [15·0–17·6])and the placebo group (15·0 months [12·6–16·1])groups (hazard ratio 0·93 [95% CI 0·79–1·09]; p=0·36). 512 (76%)of 675 patients in the trebananib group and 237 (71%)of 336 in the placebo group had grade 3 or worse treatment-emergent adverse events; of which the most common events were neutropenia (trebananib 238 [35%]vs placebo 126 [38%])anaemia (76 [11%]vs 40 [12%]), and leucopenia (81 [12%]vs 35 [10%]). 269 (40%)patients in the trebananib group and 104 (31%)in the placebo group had serious adverse events. Two fatal adverse events in the trebananib group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). No treatment-related fatal adverse events occurred in the placebo group. Interpretation: Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. The combination of trebananib plus carboplatin and paclitaxel did not produce new safety signals. These results show that trebananib in combination with carboplatin and paclitaxel is minimally effective in this patient population. Funding: Amgen. © 2019 Elsevier Ltd

  3. 3
    دورية أكاديمية

    المصدر: Department of Obstetrics & Gynecology

    الوصف: Uterine malignant mixed müllerian tumors (MMMTs) are rare and highly aggressive malignancies with poor clinical prognoses. We examined for differences in the oncoprotein profiles of primary versus recurrent MMMTs. Five cases of recurrent uterine MMMT were examined by paraffin immunohistochemistry for the expression of p53, p16, P-cadherin, and Cerb-B2. P16, p53, and P-cadherin were each expressed in 100%, 80%, and 60% of the primary cases, respectively. Three cases expressed all three oncoproteins. All five cases were negative for Cerb-B2. No difference in antigen expression was seen in the epithelial versus sarcomatous components. Primary and recurrent tumors were concordant for p53, P-cadherin, and Cerb-B2. However, three cases of recurrent tumors were negative for p16 expression. P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. Interestingly, p16 protein expression was lost in some cases of MMMTs when they recurred. This suggests that the oncoprotein and possibly genetic profile of p16 changes over time. We did not observe any difference in antigen expression between areas of epithelial or sarcomatous differentiation, which would support a single pluripotential malignant clone in the histogenesis of these tumors.

  4. 4
    دورية أكاديمية

    المصدر: International Journal of Gynecologic Cancer ; volume 16, issue 3, page 1354-1357 ; ISSN 1048-891X 1525-1438

    الوصف: Uterine malignant mixed müllerian tumors (MMMTs) are rare and highly aggressive malignancies with poor clinical prognoses. We examined for differences in the oncoprotein profiles of primary versus recurrent MMMTs. Five cases of recurrent uterine MMMT were examined by paraffin immunohistochemistry for the expression of p53, p16, P-cadherin, and Cerb-B2. P16, p53, and P-cadherin were each expressed in 100%, 80%, and 60% of the primary cases, respectively. Three cases expressed all three oncoproteins. All five cases were negative for Cerb-B2. No difference in antigen expression was seen in the epithelial versus sarcomatous components. Primary and recurrent tumors were concordant for p53, P-cadherin, and Cerb-B2. However, three cases of recurrent tumors were negative for p16 expression. P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. Interestingly, p16 protein expression was lost in some cases of MMMTs when they recurred. This suggests that the oncoprotein and possibly genetic profile of p16 changes over time. We did not observe any difference in antigen expression between areas of epithelial or sarcomatous differentiation, which would support a single pluripotential malignant clone in the histogenesis of these tumors.